Camp4 Therapeutics Corporation
CAMP
$4.36
$0.163.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 160.53% | 436.50% | -- | 759.14% | 331.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.53% | 436.50% | -- | 759.14% | 331.43% |
| Cost of Revenue | -2.59% | -1.61% | 0.88% | 1.46% | -2.62% |
| Gross Profit | 9.12% | 9.09% | 8.74% | 5.30% | 5.55% |
| SG&A Expenses | 13.86% | 16.40% | 32.55% | 36.44% | 32.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.09% | 3.39% | 8.74% | 9.64% | 5.28% |
| Operating Income | 2.40% | 1.93% | -1.50% | -4.53% | -3.07% |
| Income Before Tax | -66.69% | -55.25% | -3.68% | -4.16% | -4.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.69% | -55.25% | -3.68% | -4.16% | -4.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.69% | -55.25% | -3.68% | -4.16% | -4.71% |
| EBIT | 2.40% | 1.93% | -1.50% | -4.53% | -3.07% |
| EBITDA | 2.59% | 1.89% | -1.61% | -4.77% | -3.23% |
| EPS Basic | 95.65% | 96.72% | 97.60% | 76.62% | 56.60% |
| Normalized Basic EPS | 95.69% | 96.74% | 97.62% | 76.62% | 56.60% |
| EPS Diluted | 95.65% | 96.72% | 97.60% | 76.62% | 56.60% |
| Normalized Diluted EPS | 95.69% | 96.74% | 97.62% | 76.62% | 56.60% |
| Average Basic Shares Outstanding | 314.15% | 547.38% | 4,276.21% | 3,162.24% | 2,197.76% |
| Average Diluted Shares Outstanding | 314.15% | 547.38% | 4,276.21% | 3,162.24% | 2,197.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |